ArticleJournal for immunotherapy of cancer2024

Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer.

Bolun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.